Sandra Loggetto

Dr. Sandra Loggetto


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
SLSandra Loggetto
Sandra Loggetto

16 November 2019 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
FCFABIANNE ALTRUDA DE MORAES COSTA CARLESSE
FABIANNE ALTRUDA DE MORAES COSTA CARLESSE
LDLiane Daudt
Liane Daudt
ASAdriana Seber
Adriana Seber
ÁDÁlvaro Pimenta Dutra
Álvaro Pimenta Dutra
AMAnaly Melo
Analy Melo
Arnaldo L. ColomboArnaldo L. Colombo
Arnaldo L. Colombo
In the present paper we summarize the suggestions of a multidisciplinary group including experts in pediatric oncology and infectious diseases who reviewed the medical literature to elaborate a consensus document (CD) for the diagnosis and clinical management of invasive fungal diseases (IFDs) in children with hematologic cancer and those who underwent hematopoietic stem-cell transplantation. All major multicenter studies designed to characterize the epidemiology of IFDs in children with cancer, as well as all randomized clinical trials addressing empirical and targeted antifungal therapy were reviewed. In the absence of randomized clinical trials, the best evidence available to support the recommendations were selected. Algorithms for early diagnosis and best clinical management of IFDs are also presented. This document summarizes practical recommendations that will certainly help pediatricians to best treat their patients suffering of invasive fungal diseases.

1 January 2023 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
ECEduardo Cerello Chapchap
Eduardo Cerello Chapchap
MSMurilo Marques Almeida Silva
Murilo Marques Almeida Silva
RAReijane Alves de Assis
Reijane Alves de Assis
LKLucila Nassif Kerbauy
Lucila Nassif Kerbauy
MDMichelli da Silva Diniz
Michelli da Silva Diniz
NHNelson Hamerschlak
Nelson Hamerschlak
Magnetic resonance imaging (MRI) T2* technique is used to assess iron overload in the heart, liver and pancreas of thalassaemic patients. Optimal iron chelation and expected tissue iron response rates remain under investigation. The objective of this study was to analyse serum ferritin and the iron concentration in the heart, liver and pancreas measured by MRI T2*/R2* during regular chelation therapy in a real-world cohort of patients with thalassemia. We evaluated thalassaemic patients ≥ 7 years old undergoing chelation/transfusion therapy by MRI and assessed serum ferritin at baseline and follow-up from 2004-2011. We evaluated 136 patients, 92% major thalassaemic, with a median age of 18 years, and median baseline ferritin 2.033ng/ml (range: 59-14,123). Iron overload distribution was: liver (99%), pancreas (74%) and heart (36%). After a median of 1.2 years of follow-up, the iron overload in the myocardium reduced from 2,63 Fe mg/g to 2,05 (p 0.003). The optimal R2* pancreas cut-off was 148 Hertz, achieving 78% sensitivity and 73% specificity. However, when combining the R2* pancreas cut off ≤ 50 Hertz and a ferritin ≤ 1222 ng/ml, we could reach a negative predictive value (NPV) of 98% for cardiac siderosis. Only 28% were undergoing combined chelation at baseline assessment, which increased up to 50% on follow up evaluation. Chelation therapy significantly reduced cardiac siderosis in thalassaemic patients. In patients with moderate/severe liver iron concentration undergoing chelation therapy, ferritin levels and myocardium iron improved earlier than the liver siderosis.

16 November 2021 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
SLSandra Loggetto
Sandra Loggetto
MVMônica Pinheiro de Almeida Veríssimo
Mônica Pinheiro de Almeida Veríssimo
LDLuiz Guilherme Darrigo-Junior
Luiz Guilherme Darrigo-Junior
RSRicardo dos Santos Simões
Ricardo dos Santos Simões
WBWanderley Bernardo
Wanderley Bernardo
JBJosefina Aparecida Pellegrini Braga
Josefina Aparecida Pellegrini Braga

1 January 2013 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
SLSandra Loggetto
Sandra Loggetto
JBJosefina Aparecida Pellegrini Braga
Josefina Aparecida Pellegrini Braga
MVMônica Pinheiro de Almeida Veríssimo
Mônica Pinheiro de Almeida Veríssimo
WBWanderley Marques Bernardo
Wanderley Marques Bernardo
LMLeticia Medeiros
Leticia Medeiros
AHAndrea Thives de Carvalho Hoepers
Andrea Thives de Carvalho Hoepers
Centro de Hematologia de São PauloUniversidade Federal de São Paulo (UNIFESP) Escola Paulista de MedicinaCentro Infantil BoldriniUniversidade de São Paulo Faculdade de MedicinaAssociacao Medica BrasileiraHospital Ana CostaCentro de Hematologia e Hemoterapia de Santa CatarinaUniversidade Federal de Santa CatarinaUNIFESP, EPMSciEL

26 August 2023 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
ECEduardo Cerello Chapchap
Eduardo Cerello Chapchap
MSMurilo Marques Almeida Silva
Murilo Marques Almeida Silva
RBRonaldo Hueb Baroni
Ronaldo Hueb Baroni
AAAderson da Silva Araujo
Aderson da Silva Araujo
RAReijane Alves de Assis
Reijane Alves de Assis
NHNelson Hamerschlak
Nelson Hamerschlak
Introduction: Despite knowledge advances on extramedullary haematopoiesis (EMH) in thalassemic patients, the real picture remains an open issue. Objectives: To assess EMH prevalence in patients with thalassemia major (TM) and intermedia (TI), to describe magnetic resonance imaging (MRI) findings and to explore clinical risk factors. Methods: In this cross-sectional study, images and clinical records of 184 consecutive patients with thalassemia who underwent T2* MRI between 2004 and 2011 were reviewed. Association of EMH with survival was investigated for patients with available follow-up charts. Results: EMH was detected in 16/168 (9.5%) patients with TM (aged 19-49 years) and in 3/16 (18.8%) with TI (aged 36-41 years). Most (88%) had paravertebral thoracic and/or abdominal masses. Age was significantly associated with EMH risk (hazard ratio, [HR] 1.10/year; confidence interval [CI]: 1.03-1.18; p-value < 0.001), while lower pancreatic iron content by T2*MRI (HR: 0.94/ms; CI: 0.89-0.99; p-value = 0.049) was a protective factor. Estimated survival rate was superior for EMH-positive (n = 19) when compared to EMH-negative patients (n = 75) (p-value = 0.013). Conclusions: The prevalence of EMH was 10.3% (19/184), presented mainly as tumoral masses of 3 to 10 cm. Age was a risk factor for EMH development, while lower pancreatic iron might be a protective factor in this cohort. (c) 2023 Associa & ccedil;& atilde;o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).